Mısır - İngilizce - EDA (Egyptian Drug Authority)

aug pharma - coated tablet - 40 mg

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxycillin; clavulanic acid -

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ketotifen fumarate 345 µg/ml equivalent to ketotifen 250 µg/ml;   - eye drops, solution - 0.25 mg/ml - active: ketotifen fumarate 345 µg/ml equivalent to ketotifen 250 µg/ml   excipient: benzalkonium chloride glycerol sodium hydroxide water for injection - treatment and prevention of signs and symptoms of seasonal allergic conjunctivitis.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ketotifen fumarate 345 µg/ml equivalent to ketotifen 250 µg/ml;   - eye drops, solution - 250 mcg/ml - active: ketotifen fumarate 345 µg/ml equivalent to ketotifen 250 µg/ml   excipient: glycerol sodium hydroxide water for injection - treatment and prevention of signs and symptoms of seasonal allergic conjunctivitis.

Singapur - İngilizce - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate eqv amoxycillin; potassium clavulanate eqv clavulanic acid - tablet, film coated - 500 mg - amoxycillin trihydrate eqv amoxycillin 500 mg; potassium clavulanate eqv clavulanic acid 125 mg

Singapur - İngilizce - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate 1004.43mg eqv amoxycillin; potassium clavulanate 148.91mg eqv clavulanic acid - tablet, film coated - 875 mg - amoxycillin trihydrate 1004.43mg eqv amoxycillin 875 mg; potassium clavulanate 148.91mg eqv clavulanic acid 125 mg

Malezya - İngilizce - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - amoxycillin sodium; clavulanic acid -

Malezya - İngilizce - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - amoxycillin sodium; clavulanic acid -

ABD - İngilizce - NLM (National Library of Medicine)

usantibiotics, llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - augmentin es-600 is indicated for the treatment of pediatric patients with - recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics less than or equal to 2 mcg/ml), h. influenzae (including β-lactamase-producing strains), or m. catarrhalis (including β-lactamase-producing strains) characterized by the following risk factors:      - antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) daycare attendance [s ee microbiology (12.4) ]. limitations of use acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. augmentin es-600 is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic greater than or equal to 4 mcg/ml. therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both s. pneumoniae (penicillin mic less than or equal to 2 mcg/ml) and the

İsrail - İngilizce - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - powder for suspension - amoxicillin as trihydrate 600 mg / 5 ml; clavulanic acid as potassium salt 42.9 mg / 5 ml - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - augmentin es is indicated for the treatment of acute otitis media in children aged at least 3 months and less than 40 kg body weight, caused or thought likely to be caused by penicillin-resistant streptococcus pneumoniae:consideration should be given to official guidance on the appropriate use of antibacterial agents.